AG
DNTH icon

Artal Group’s Dianthus Therapeutics DNTH Stock Holding History

Artal Group’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-28,125
Closed -$3.38M – 145
2020
Q2 		$3.38M Buy
+28,125
New +$3.96M 0.09% 115
2019
Q3 		– Sell
-1,470
Closed -$347K – 107
2019
Q2 		$347K Sell
1,470
-11,030
-88% -$2.73M 0.01% 103
2019
Q1 		$3.29M Hold
12,500
– – 0.13% 89
2018
Q4 		$1.14M Hold
12,500
– – 0.04% 101
2018
Q3 		$2.4M Hold
12,500
– – 0.06% 96
2018
Q2 		$2.7M Buy
+12,500
New +$2.82M 0.06% 88

Other funds holding DNTH

TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Artal Group's DNTH Position: Q3 2020 in Review

Artal Group sold out of Dianthus Therapeutics (DNTH) in Q3 2020, closing a stake of 28,125 shares — an estimated $3.38M sold.

Artal Group first reported a position in DNTH in Q2 2018 and held it in 6 quarters. The position peaked at $3.38M in Q2 2020. 94 funds tracked by Wall St. Rank hold DNTH as of Q3 2020.

  • Artal Group reported no remaining Dianthus Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Artal Group sold 28,125 Dianthus Therapeutics shares in Q3 2020, an estimated $3.38M.
  • Artal Group first reported a position in Dianthus Therapeutics in Q2 2018 and held it in 6 quarters.
  • Artal Group's Dianthus Therapeutics position peaked at $3.38M in Q2 2020.
  • 94 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q3 2020.

Based on Artal Group's 13F filing for Q3 2020, filed 13 Nov 2020.